Literature DB >> 26927611

Targeting constitutively active androgen receptor splice variants in castration resistant prostate cancer.

M T Schweizer1,2, S R Plymate3.   

Abstract

Entities:  

Keywords:  Androgen receptor; drug resistance; prostate cancer; splice variants

Mesh：

Substances：

Year:  2016        PMID： 26927611      PMCID： PMC4975933          DOI： 10.1517/14728222.2016.1159676

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN： 1472-8222            Impact factor:   6.902


× No keyword cloud information.
  29 in total

1.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.

Authors:  Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate
Journal:  J Clin Invest       Date:  2010-07-19       Impact factor: 14.808

2.  The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way.

Authors:  Sanjay N Mediwala; Huiying Sun; Adam T Szafran; Sean M Hartig; Guru Sonpavde; Teresa G Hayes; Perumal Thiagarajan; Michael A Mancini; Marco Marcelli
Journal:  Prostate       Date:  2012-07-20       Impact factor: 4.104

3.  Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.

Authors:  Elahe A Mostaghel; Brett T Marck; Stephen R Plymate; Robert L Vessella; Stephen Balk; Alvin M Matsumoto; Peter S Nelson; R Bruce Montgomery
Journal:  Clin Cancer Res       Date:  2011-08-01       Impact factor: 12.531

4.  Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes.

Authors:  Duo Xu; Yang Zhan; Yanfeng Qi; Bo Cao; Shanshan Bai; Wei Xu; Sanjiv S Gambhir; Peng Lee; Oliver Sartor; Erik K Flemington; Haitao Zhang; Chang-Deng Hu; Yan Dong
Journal:  Cancer Res       Date:  2015-06-09       Impact factor: 12.701

5.  Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Authors:  Yingming Li; Majid Alsagabi; Danhua Fan; G Steven Bova; Ahmed H Tewfik; Scott M Dehm
Journal:  Cancer Res       Date:  2011-01-19       Impact factor: 12.701

6.  FOXO1 binds to the TAU5 motif and inhibits constitutively active androgen receptor splice variants.

Authors:  Laura R Bohrer; Ping Liu; Jian Zhong; Yunqian Pan; James Angstman; Lucas J Brand; Scott M Dehm; Haojie Huang
Journal:  Prostate       Date:  2013-02-06       Impact factor: 4.104

7.  Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.

Authors:  Yingming Li; Siu Chiu Chan; Lucas J Brand; Tae Hyun Hwang; Kevin A T Silverstein; Scott M Dehm
Journal:  Cancer Res       Date:  2012-11-01       Impact factor: 12.701

8.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.

Authors:  Eleni Efstathiou; Mark Titus; Sijin Wen; Anh Hoang; Maria Karlou; Robynne Ashe; Shi Ming Tu; Ana Aparicio; Patricia Troncoso; James Mohler; Christopher J Logothetis
Journal:  Eur Urol       Date:  2014-05-29       Impact factor: 20.096

9.  Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies.

Authors:  Siu Chiu Chan; Luke A Selth; Yingming Li; Michael D Nyquist; Lu Miao; James E Bradner; Ganesh V Raj; Wayne D Tilley; Scott M Dehm
Journal:  Nucleic Acids Res       Date:  2015-04-23       Impact factor: 16.971

10.  An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Authors:  Jae-Kyung Myung; Carmen A Banuelos; Javier Garcia Fernandez; Nasrin R Mawji; Jun Wang; Amy H Tien; Yu Chi Yang; Iran Tavakoli; Simon Haile; Kate Watt; Iain J McEwan; Stephen Plymate; Raymond J Andersen; Marianne D Sadar
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808
View more
  3 in total

1.  A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Authors:  Michael T Schweizer; Kathleen Haugk; Jožefa S McKiernan; Roman Gulati; Heather H Cheng; Jessica L Maes; Ruth F Dumpit; Peter S Nelson; Bruce Montgomery; Jeannine S McCune; Stephen R Plymate; Evan Y Yu
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

Review 2.  Using biochemistry and biophysics to extinguish androgen receptor signaling in prostate cancer.

Authors:  Irfan Asangani; Ian A Blair; Gregory Van Duyne; Vincent J Hilser; Vera Moiseenkova-Bell; Stephen Plymate; Cynthia Sprenger; A Joshua Wand; Trevor M Penning
Journal:  J Biol Chem       Date:  2021-01-09       Impact factor: 5.157

Review 3.  Intracrine androgen biosynthesis and drug resistance.

Authors:  Trevor M Penning; Irfan A Asangani; Cynthia Sprenger; Stephen Plymate
Journal:  Cancer Drug Resist       Date:  2020-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.